Background
==========

Optic nerve hypoplasia (ONH) is a congenital anomaly often associated with hypopituitarism and brain malformations. It is relatively rare, with an incidence of 1 in 10,000 live births, and it equally affects boys and girls \[[@B1]\]. The term septo-optic dysplasia (SOD), historically and even today, is widely used interchangeably with that of ONH. However, it is now known that absence of the septum pellucidum *per se*does not confer increased risk for growth hormone (GH) deficiency alone or as a component of hypopituitarism in children with ONH \[[@B2],[@B3]\].

In a study of 47 subjects \[age (mean ± SD) 15.2 ± 10.6 months\] with ONH followed until 59.0 ± 6.2 months of age, Ahmad, *et al*reported a prevalence of endocrinopathies of 71.7% (including 64.1% with GH-IGF-I axis abnormalities); these were not associated with ONH laterality, absence of septum pellucidum, or pituitary abnormalities on neuro-imaging \[[@B2]\]. The only prior large, long-term study looking at growth outcomes in children described as having SOD treated with GH included 582 children enrolled in the National Cooperative Growth Study (NCGS) (Genentech, S. San Francisco CA). Among this cohort, 71 reached near-adult height (NAH) (mean -1.57 ± 1.27 SD), representing a mean gain of 1.17 ± 1.49 SD after 6-7 years of GH treatment \[[@B4]\].

More recently, it has been suggested that obesity is a frequent occurrence in children with ONH perhaps on a hypothalamic basis \[[@B5],[@B6]\]. In his cohort of 47 subjects with ONH, Ahmad found that 44% had a body mass index (BMI) \> 85^th^percentile at 5 years of age \[[@B2]\]. In the large NCGS study, no weight or BMI data were reported \[[@B4]\].

The purpose of the current analyses is to compare presenting features and short- and long-term auxological outcomes of GH treatment in children with ONH to those of patients with congenital growth hormone deficiency (CGHD) without non-pituitary midline defects or ONH using data from KIGS (the Pfizer International Growth Database).

Methods
=======

The KIGS database, established in 1987 and containing data from over 70,000 patients in 51 different countries, is an international registry developed with the main objective of documenting the long-term outcomes and safety of Somatonorm^®^and Genotropin^®^GH products (Pfizer, Inc). The KIGS survey is performed in accordance with the recommendations adopted by the 18^th^World Medical Assembly (held in Helsinki, Finland in 1964) and any subsequent revisions which exist to guide physicians carrying out biomedical research involving human individuals. Each subject and/or his/her legal representative receive adequate information, has the right to withdraw from the survey at any time, and consents his/her participation, although, during the first decade of its existence, this kind of registry or non-interventional trial that KIGS represents did not require informed consent from the subjects or legally acceptable representatives in many countries.

To capture subject data from KIGS for the current investigation, we included the diagnoses, ONH *and/or*SOD, since the latter is still widely used to describe patients with ONH whether or not the presence of the septum pellucidum is documented. Hereafter, for simplicity, we refer to the study condition as ONH/SOD. As of January 2009, there were 565 subjects identified as having CGHD secondary to ONH/SOD and 244 control subjects with CGHD unrelated to ONH/SOD and without extra-pituitary midline pathology. A list of the diagnostic codes included in the non-ONH/SOD CGHD group is included in Table [1](#T1){ref-type="table"}. Subjects that were prepubertal and had at least one year of longitudinal data while receiving GH were included in the data analysis (ONH/SOD group n = 395 and CGHD group n = 158).

###### 

KIGS diagnostic codes included in non-ONH/SOD CGHD (cross-sectional numbers)

  KIGS Diagnostic Codes   n         Description
  ----------------------- --------- -------------------------------------------------
  2.1.1.1                 23        *GH*gene-defect (Type 1A dominant or recessive)
  2.1.1.2                 25        *GH*gene-defect
  2.1.1.3                 4         *GHRH*gene-defect
  2.1.1.9                 192       Other genetic cause of GHD
                                    
  **Total**               **244**   

GH, growth hormone; GHRH, growth hormone releasing hormone; GHD, growth hormone deficiency

Background demographic characteristics, birth measurements, GH stimulation test results, and prevalence of associated hypothalamic-pituitary deficiencies affecting thyroid function, glucocorticoid production, and water metabolism (diabetes insipidus) were collected from KIGS. The prevalence of hypogonadism could only be obtained in older subjects who reached NAH. The subjects\' additional hormonal deficiencies were also managed by their treating physicians. Auxological data at the time of initiation of GH therapy and after one year of treatment were also collected. Similar data of the subsets of the two groups who attained NAH were compared. NAH was defined by height velocity (\< 2 cm/year), bone age (≥ 14 years in females or ≥ 16 years in males), and/or chronological age (\> 15 years in females and \> 17 years in males).

Growth parameters are reported as standard deviation scores (SDS) which were calculated based on standards from Prader *et al*\[[@B7]\] and, for weight data, from Freeman *et al*\[[@B8]\]. Birth weight and length SDS were calculated using the reference of Niklasson *et al*\[[@B9]\]. Bone age readings were taken as reported by physicians and were based on the methods of Greulich and Pyle \[[@B10]\] or Tanner *et al*\[[@B11],[@B12]\]. Data were not normally distributed and, therefore, are presented as median and 10^th^and 90^th^percentiles. Wilcoxon rank-sum test was used to detect differences between the two groups.

The heights of subjects in both groups were analyzed using the previously published KIGS prediction model for idiopathic GHD excluding GH maximum peak \[[@B13]\]. Differences between observed and predicted height velocities are expressed in terms of Studentized residuals. The residual is calculated as the observed height velocity minus the predicted height velocity for each observation, and the Studentized residual is the residual divided by its standard error.

Results
=======

Background characteristics were compared between the two groups (Table [2](#T2){ref-type="table"}). The birth length and weight SDS were significantly greater in the ONH/SOD group compared to the non-ONH/SOD CGHD group \[birth length SDS median (0.27); 10^th^and 90^th^percentiles (-1.3, 2.0) vs. median (-0.62); 10^th^and 90^th^percentiles (-2.5, 1.2); p \< 0.001) and birth weight SDS (-0.31; -1.7, 1.1) vs. (-0.58; -2.0, 1.0); p = 0.021)\]. Mid-parental height SDS was also significantly greater in the ONH/SOD group (-0.23; -1.8, 1.3) compared to the non-ONH/SOD CGHD group \[(-1.04; -3.0, 0.5); p \< 0.001\]. Peak GH levels on stimulation testing were similar between the two groups. The ONH/SOD group had significantly more subjects with other hypothalamic-pituitary hormone deficiencies compared to the non-ONH/SOD CGHD group (72.7% vs. 51.9%; p \< 0.001), with involvement of the thyroid and adrenal axes being the most common.

###### 

Characteristics at background, GH start, and 1^st^year on GH

                                         ONH/SOD                                               Non-ONH/SOD                                                     
  -------------------------------------- ----------------------------------------------------- ------------- -------------- ----- ------------- -------------- ----------
                                         *Background*                                                                                                          
  Gender, males                          395                                                   227 (57.5%)                  158   101 (63.9%)                  
  Birth Length SDS                       206                                                   0.27          -1.3, 2.0      104   -0.62         -2.5, 1.2      \< 0.001
  Birth Weight SDS                       349                                                   -0.31         -1.7, 1.1      133   -0.58         -2.0, 1.0      0.021
  Mid-Parental Height SDS                324                                                   -0.23         -1.8, 1.3      140   -1.04         -3.0, 0.5      \< 0.001
  Peak GH (μg/L)                         307                                                   2.60          0.8, 7.2       131   3.30          0.5, 10.8      0.053
  Other Pituitary Hormone Deficiencies   395                                                   287 (72.7%)                  158   82 (51.9%)                   \< 0.001
   Hypothyroidism                        395                                                   250 (63.3%)                  158   74 (46.8%)                   \< 0.001
   Glucocorticoid deficiency             395                                                   206 (52.2%)                  158   46 (29.1%)                   \< 0.001
   Diabetes insipidus                    395                                                   51 (12.9%)                   158   6 (3.8%)                     \< 0.001
                                         *At GH Start*                                                                                                         
  Age (years)                            395                                                   3.99          0.9, 9.8       158   4.47          0.7, 10.7      0.498
  Bone Age (years)                       77                                                    3.50          1.4, 8.7       41    4.00          1.2, 10.0      0.784
  Height SDS                             395                                                   -3.00         -4.8, -0.9     158   -3.68         -6.7, -1.9     \< 0.001
  Height - Mid-Parental Height SDS       324                                                   -2.74         -4.67, -0.62   140   -2.42         -4.94, -0.72   0.305
  Height Velocity (cm/year)              147                                                   5.46          2.35, 12.07    45    5.23          3.19, 9.76     0.904
  Weight SDS                             395                                                   -1.56         -4.2, 0.5      158   -2.56         -5.7, -0.6     \< 0.001
  BMI SDS                                395                                                   0.22          -1.8, 2.1      158   -0.18         -2.1, 1.6      0.001
  GH Dose (mg/kg/week)                   395                                                   *0*.24        0.16, 0.33     158   0.22          0.16, 0.39     0.395
                                         *1st yr on GH*                                                                                                        
  Age (years)                            395                                                   5.01          1.87, 10.74    158   5.46          1.64, 11.75    0.500
  Bone Age (years)                       96                                                    4.40          2.00, 9.00     53    4.17          2.00, 11.5     0.429
  Height SDS                             395                                                   -1.95         -4.0, 0.0      158   -2.37         -4.7, -0.9     \< 0.001
  Δ Height SDS                           395                                                   1.02          0.0, 2.0       158   1.10          0.3, 2.7       0.066
  Height - Mid-Parental Height SDS       324                                                   -1.70         -3.78, 0.29    140   -1.29         -3.15, 0.23    0.010
  Height Velocity (cm/year)              395                                                   11.25         6.74, 16.18    158   10.54         6.98, 18.97    0.863
  Weight SDS                             393                                                   -0.91         -3.3, 1.3      158   -1.81         -3.9, -0.0     \< 0.001
  BMI SDS                                393                                                   0.05          -1.8, 2.3      158   -0.43         -2.1, 1.2      \< 0.001
  GH Dose (mg/kg/week)                   388                                                   0.23          0.14, 0.33     156   0.21          0.13, 0.33     0.068
                                         *IGHD Prediction Model (Without GH Peak) at 1 year*                                                                   
  Predicted Height Velocity              186                                                   10.69         9.03, 12.51    73    9.99          8.28, 11.86    \< 0.001
  Actual Height Velocity (cm/year)       186                                                   10.72         6.66, 14.37    73    9.49          7.16, 13.77    0.305
  Studentized Residual                   186                                                   -0.11         -2.53, 1.98    73    -0.04         -1.61, 1.95    0.565

SDS, standard deviation score; GH, growth hormone

At the start of GH therapy, both groups had similar chronological ages and bone ages. However, the ONH/SOD group had significantly greater height SDS \[(-3.00; -4.8, -0.9) vs. (-3.68; -6.7, -1.9); p \< 0.001\], weight SDS \[(-1.56; -4.2, 0.5) vs. (-2.56; -5.7, -0.6); p \< 0.001\], and BMI SDS \[(0.22; -1.8, 2.1) vs. (-0.18; -2.1, 1.6); p = 0.001\] (Table [2](#T2){ref-type="table"}).

After one year on GH therapy, the two groups had similar changes in height SDS (p = 0.066). The ONH/SOD group continued to have a significantly higher height SDS, weight SDS, and BMI SDS after one year of GH therapy (all p \< 0.001). However, height SDS corrected for family height genetics was significantly greater in the comparator group after the first year of GH treatment (Figure [1](#F1){ref-type="fig"}). Use of the prediction model for first-year growth response in children with idiopathic GHD showed that, although there was a slightly greater than predicted response in the ONH/SOD group versus the non-ONH/SOD CGHD group, there was no difference in actual height response between both groups, with Studentized residuals equivalent in both groups (Figure [2](#F2){ref-type="fig"}).

![**Comparison between groups**. Comparison between groups with ONH/SOD vs. non-ONH/SOD CGHD of (a) height SDS, (b) height - MPH SDS, (c) weight SDS, and (d) BMI SDS at start and after 1 year of GH therapy.](1687-9856-2011-17-1){#F1}

![**Differences between observed and predicted height velocities**. Differences between observed and predicted height velocities after 1 year of GH therapy in (a) ONH/SOD group and (b) non-ONH/SOD CGHD group were expressed in terms of Studentized residuals.](1687-9856-2011-17-2){#F2}

NAH data were available for 59 subjects in the ONH/SOD group and 23 subjects in the non-ONH/SOD CGHD group (Table [3](#T3){ref-type="table"}). The two groups had similar NAH at approximately -1 SDS (p = 0.430). The non-ONH/SOD CGHD attained a NAH that was closer to their mid-parental height (p \< 0.05). The two groups had similar weight SDS and BMI SDS at time of NAH (Figure [3](#F3){ref-type="fig"}). At NAH, the two groups had the same prevalence of hypogonadism.

###### 

Characteristics at Near-Adult Height

                                      ONH/SOD         Non-ONH/SOD                                                   
  ----------------------------------- --------------- ------------- -------------- ---- ------------ -------------- ----------
                                      *At GH Start*                                                                 
  Gender, males                       59              26 (44.1%)                   23   10 (43.5%)                  
  Age (years)                         59              5.64          2.14, 11.76    23   5.12         2.09, 12.04    0.546
  Height SDS                          59              -3.77         -5.51, -1.96   23   -4.97        -7.73, -2.98   \< 0.001
  Height - Mid-Parental Height SDS    48              -3.41         -5.85, -1.78   22   -3.30        -5.81, -0.91   0.658
  Weight SDS                          59              -2.23         -4.44, -0.72   23   -3.49        -5.92, -0.80   0.013
  BMI SDS                             59              -0.13         -2.02, 1.86    23   0.09         -1.64, 1.56    0.955
  GH Dose (mg/kg/week)                59              0.21          0.14, 0.31     23   0.21         0.14, 0.43     0.996
                                      *At NAH*                                                                      
  Age (years)                         59              17.73         15.5, 20.5     23   17.30        15.3, 19.4     0.369
  Height SDS                          59              -0.87         -2.8, 0.6      23   -1.37        -2.7, 0.2      0.430
  Δ Height SDS (Latest minus Start)   59              2.75          1.1, 4.4       23   3.37         1.6, 6.1       0.025
  Height - Mid-Parental Height SDS    48              -0.63         -2.35, 0.87    22   0.37         -1.59, 1.43    0.004
  Weight SDS                          59              -0.53         -2.6, 2.7      23   -0.22        -2.1, 1.9      0.988
  BMI SDS                             59              0.32          -1.90, 2.50    23   0.59         -0.90, 2.50    0.581
  Mean Total GH Dose (mg/kg/week)     59              0.19          0.13, 0.28     23   0.19         0.14, 0.25     0.722
  Years on GH Treatment               59              11.15         6.69, 16.37    23   11.51        6.71, 14.69    0.996
  Hypogonadism                        59              23 (39.0%)                   23   9 (39.1%)                   

SDS, standard deviation score; GH, growth hormone

![**Comparison between groups with ONH/SOD vs. non-ONH/SOD CGHD**. Comparison between groups with ONH/SOD vs. non-ONH/SOD CGHD of (a) height SDS, (b) height - MPH SDS, (c) weight SDS, and (d) BMI SDS at near-adult height.](1687-9856-2011-17-3){#F3}

Discussion
==========

Although over half of the patients with ONH/SOD will develop an abnormality in their GH-IGF-I axis \[[@B2]\], little is known about their clinical presentations and auxological responses to GH, especially in comparison to those of similar patients with non-ONH/SOD CGHD.

In our study, the birth length and weight were significantly greater in the ONH/SOD group. It is unclear whether these differences can be fully explained by the increased mid-parental height seen in the ONH/SOD group or if there might be other disease-specific explanations. Some of this difference in mid-parental height may be due to the parents of those children with non-ONH/SOD CGHD also having the same gene defect causing short stature. At the time of diagnosis, the two groups had similar stimulated peak GH levels suggesting a comparable degree of GH deficiency.

The higher prevalence of pituitary hormone deficiencies seen in the ONH/SOD group compared to the non-ONH/SOD CGHD group is not surprising given the known association of ONH/SOD with hypopituitarism. However, our study found, at the time of GH initiation, for no obvious reason, a much higher prevalence of associated hormone deficiencies in the ONH/SOD group compared to the data reported in the NCGS study (hypothyroidism: 63.2% vs 27%, glucocorticoid deficiency: 52.2% vs 24%, and diabetes insipidus: 12.9% vs 5%) \[[@B4]\]. In a smaller subset who reached NAH, 39% of subjects in our cohort had hypogonadism while this data was not reported in the NCGS study.

At the time of GH initiation, the ONH/SOD group was significantly larger than the non-ONH/SOD CGHD group in all measures (height, weight, and BMI). The taller heights at diagnosis in the ONH/SOD group might relate to the associated ophthalmological manifestations of the condition leading to nystagmus and earlier referral. This group\'s greater genetic height potential might also be contributory. As for the higher weight and BMI, this may be associated with the intrinsic hypothalamic dysfunction seen in some patients with ONH/SOD causing hyperphagia.

The two groups responded similarly to one year of GH therapy with a comparable increase in height and similar to that predicted using the KIGS-derived prediction model for first-year growth in GH-treated children with idiopathic GHD. As a result, the ONH/SOD group continued to have significantly greater height, along with weight and BMI, than did the non-ONH/SOD CGHD group. Although we recognize the small size of the subsets from both groups that attained NAH and the inherent uncertainty of being able to draw firm conclusions as a result, the available data suggest that the two groups have similar height, weight, and BMI at NAH. With height outcomes in both groups within 1 SD of the mean (corrected for their respective mid-parental heights), this suggests that there is excellent adult height potential in children with congenital GH deficiency. Furthermore, these results suggest that long-term GH therapy can possibly prevent, minimize, and/or reverse the obesity that has been described in patients with ONH/SOD. Additional randomized prospective studies of GH therapy in patients with ONH/SOD are needed to investigate the effects of GH therapy specifically on obesity and body composition.

In summary, children with ONH/SOD have different presenting characteristics, but similar and normal final height responses to GH therapy compared to children with non-ONH/SOD CGHD. Because ONH/SOD is a major risk factor for CGHD and these patients may not be as short as those with non-ONH/SOD CGHD, it is important for clinicians to have a high index of suspicion and begin screening these patients for CGHD as early as possible. GH therapy may have additional benefits in this patient population as well with regard to body composition thus making early diagnosis and treatment even more important.
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